Navigation Links
MEI Pharma Adds Cancer Drug Development Veteran Tom Reynolds to Board of Directors
Date:2/11/2013

nd Ph.D. in Biophysics from Stanford University and a B.A. in Chemistry from Dartmouth College.

"I am delighted to join the Board of MEI Pharma at such an exciting time for the company," said Dr. Reynolds. "I believe that MEI Pharma is poised to make an immediate impact in the oncology arena with its lead drug candidate, Pracinostat. I look forward to working closely with the rest of the Board and management team to execute the optimal clinical development and marketing approval strategy for Pracinostat and ultimately realize its significant potential."

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor being developed for advanced hematologic malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in combination with azacitidine in patients with advanced MDS were presented at the American Society of Hematology Annual Meeting in December 2012 showing an overall response rate (CR+CRi+PR) of 89% (eight out of nine). The Company plans to initiate a randomized, placebo-controlled Phase II trial of Pracinostat in combination with azacitidine in patients with MDS by June 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nat
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Adipic ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/24/2014)... 24, 2014 Senior Vice President, ... dynamic leadership skills, business acumen Elsevier ... information products and services, congratulates Diane Bartoli , ... and Workflow, Elsevier Clinical Solutions, for being recognized in ... Awards issue of Profiles in Diversity Journal ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp was a ... with great people and take risks to achieve success. ... at his extraordinarily courageous attitude when taking on challenges. ... with his death impending—that’s how he continued looking for ... take his life. , Carrying on Sharp’s relentless dream ...
(Date:11/22/2014)... 21, 2014 RURO, Inc., a ... has released Limfinity® version 5.1.4. , RURO’s deployment ... Limfinity® than ever in RURO’s 8 year history. ... framework enhancement. Limfinity® version 5.1.4 is the perfect ... beyond bug fixes! , Limfinity® 5.1.4 release highlights ...
Breaking Biology Technology:Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3RURO Announces Limfinity® version 5.1.4 2
... Mylan Inc. (NYSE: MYL ),announced today ... wholly,owned subsidiary of Forest Laboratories, Inc. (NYSE: ... commercialize, develop and distribute the,novel beta blocker Bystolic(TM) ... for the treatment of hypertension. The companies have,agreed ...
... NexGen Biofuels Ltd.,(f/k/a Healthcare Technologies Ltd.) (the ... Company received a letter from the Nasdaq Listing,Qualification ... determined to,delist the Company,s ordinary shares from The ... of the Nasdaq Listing Qualifications,Department that the Company ...
... Cauley Bowman Carney &,Williams, PLLC announces an investigation ... CGPI ). On February 26, 2008,CollaGenex announced ... agreement,with an affiliate of Galderma Pharma S.A. Under ... $16.60 per share in cash for each,share owned. ...
Cached Biology Technology:Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 2Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 3
(Date:11/7/2014)... SPRINGS, Florida , November 6, 2014 ... secure authentication for better mobile security revolutionizing online transactions.  Companies ... ), Alibaba Holdings Ltd. (NYSE: BABA ), Google ... MSFT ), eBay Inc. (NASDAQ: EBAY ) ... NXTD and NXTDW), a biometric authentication company ...
(Date:11/6/2014)... Medicine, Inc, a Baltimore-based bioinformatics company focused on ... a research collaboration with the international leader in ... CSBR). , "There are many companies utilizing advances ... TumorGraft technology is unique in a way that ... vast amounts of valuable data. Our bioinformatic analysis ...
(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2
... mineral supplements can enhance mental energy and well-being not ... anxiety and depression, according to a July 15 panel ... Annual Meeting & Food Expo held at McCormick Place. ... medicine at the University of Calgary, Alberta, Canada, said ...
... USA The Geological Society of America will recognize ... at its 2013 Annual Meeting & Exposition in Denver, ... Arthur L. Day Medal, and the Young Scientist Award ... of the University of Hawaii, Richard W. Carlson of ...
... amino and fatty acids to the diets of youth with ... insulin for up to two years after diagnosis, said researchers ... University of North Carolina at Chapel Hill. The ... risk of diabetes complications by continuing to produce some of ...
Cached Biology News:2013 medals and awards of the Geological Society of America 2Diet additions may help youth with type 1 diabetes keep producing own insulin 2
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... White lyophilized solid. PROTECT FROM ... reversible inhibitor of γ-secretase. Equipotently inhibits the ... = 2.6 μM) and Aβ x-42 ... in HEK293 cells stably transfected with the ...
...
Biology Products: